United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - trimethoprim - oral tablet - 100mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

crescent pharma ltd - trimethoprim - oral tablet - 100mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - trimethoprim - oral tablet - 100mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - trimethoprim - oral tablet - 200mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

mawdsley-brooks & company ltd - trimethoprim - oral tablet - 100mg

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - trimethoprim sulfate (unii: e377mf8eq8) (trimethoprim - unii:an164j8y0x), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k) - trimethoprim sulfate and polymyxin b sulfate ophthalmic solution is indicated in the treatment of surface ocular bacterial infections, including acute bacterial conjunctivitis, and blepharoconjunctivitis, caused by susceptible strains of the following microorganisms: staphylococcus aureus, staphylococcus epidermidis, streptococcus pneumoniae, streptococcus viridans, haemophilus influenza and pseudomonas aeruginosa. * *efficacy for this organism in this organ system was studied in fewer than 10 infections. trimethoprim sulfate and polymyxin b sulfate ophthalmic solution is contraindicated in patients with known hypersensitivity to any of its components.

United States - English - NLM (National Library of Medicine)

golden state medical supply, inc. - trimethoprim (unii: an164j8y0x) (trimethoprim - unii:an164j8y0x) - to reduce the development of drug-resistant bacteria and maintain the effectiveness of trimethoprim tablets, usp and other antibacterial drugs, trimethoprim tablets, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. for the treatment of initial episodes of uncomplicated urinary tract infections due to susceptible strains of the following organisms: escherichia coli , proteus mirabilis , klebsiella pneumoniae , enterobacter species, and coagulase-negative staphylococcus species, including s. saprophyticus . cultures and susceptibility tests should be performed to determine the susceptibility of

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - trimethoprim, quantity: 16 mg/ml; sulfamethoxazole, quantity: 80 mg/ml - injection, concentrated - excipient ingredients: sodium metabisulfite; propylene glycol; ethanol; diethanolamine; sodium hydroxide; water for injections; hydrochloric acid - indications as at 31 october 2003 :parenteral administration of sulfamethoxazole/trimethoprim is indicated where oral dosage is not desirable or practical, e.g. pre- and post-operative infections associated with surgery, trauma or gynaecology; septicaemia and other infections due to sensitive organisms such as typhoid and paratyphoid.

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - trimethoprim (unii: an164j8y0x) (trimethoprim - unii:an164j8y0x) - to reduce the development of drug-resistant bacteria and maintain the effectiveness of trimethoprim tablets, usp and other antibacterial drugs, trimethoprim tablets, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. for the treatment of initial episodes of uncomplicated urinary tract infections due to susceptible strains of the following organisms: escherichia coli , proteus mirabilis , klebsiella pneumoniae , enterobacter species, and coagulase-negative staphylococcus species, including s. saprophyticus . cultures and susceptibility tests should be performed to determine the susceptibility of the bacteria to trimethoprim. therapy may be initiated prior to obtaining the

United States - English - NLM (National Library of Medicine)

advanced rx pharmacy of tennessee, llc - trimethoprim (unii: an164j8y0x) (trimethoprim - unii:an164j8y0x), sulfamethoxazole (unii: je42381tnv) (sulfamethoxazole - unii:je42381tnv) - indications and usage to reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. urinary tract infections: for the treatment of urinary tract infections due to susceptible strains of the following organisms: escherichia coli, klebsiella species, enterobacter species, morganella morganii, proteus mirabilis and proteus vulgaris. it is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. a